
    
      This study will be in 24 non-smoking outpatients with schizophrenia or schizoaffective
      disorder. Subjects will complete three treatment phases, each involving 5 straight days of
      taking AVL-3288 (10 mg or 30 mg study drug or placebo) followed by a 16 day washout period in
      which subjects do not take the study drug to ensure that the drug is completed eliminated
      from the body before the next phase.
    
  